|
|
Article: Neurocrine's 'RESTFUL' Study Demonstrates Highly Positive Long-Term Efficacy Results with Indiplon Immediate Release; Sustained Effects on Sleep Initiation and Sleep Quality Over Entire Treatment Period.
- Article from:
- PR Newswire
- Article date:
- March 24, 2004
CopyrightCOPYRIGHT 2004 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Neurocrine Biosciences, Inc. today announced positive results from the pivotal long term efficacy and safety Phase III "RESTFUL" trial with indiplon immediate release in patients with chronic insomnia, achieving highly statistically significant results in sleep initiation and sleep quality that were sustained over a three month period. The study involved 700 adult patients, ages 21 to 64 years, with chronic insomnia, in which patients received nightly administration of indiplon immediate release (10 mg or 20 mg) over the three-month period. Results demonstrated that with either of two dose levels of indiplon immediate release, patients achieved rapid sleep onset and slept ...